These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28502608)

  • 1. The switch to infliximab biosimilars.
    Veselý R; Richardson P
    Lancet; 2017 Jun; 389(10086):2266-2268. PubMed ID: 28502608
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch?
    Scott FI
    Dig Dis Sci; 2020 Aug; 65(8):2158-2160. PubMed ID: 32338328
    [No Abstract]   [Full Text] [Related]  

  • 3. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
    Katsanos KH; Papamichael K; Cheifetz AS; Christodoulou DK
    Inflamm Bowel Dis; 2018 Feb; 24(3):465-466. PubMed ID: 29462402
    [No Abstract]   [Full Text] [Related]  

  • 4. Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.
    Husereau D; Feagan B; Selya-Hammer C
    Appl Health Econ Health Policy; 2018 Jun; 16(3):279-288. PubMed ID: 29411318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars.
    Pouillon L; Allocca M; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2018 Sep; 48(5):574-575. PubMed ID: 30156324
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply.
    Goncalves J; Magro F; Danese S; Lakatos PL; Ben-Horin S
    Aliment Pharmacol Ther; 2018 Sep; 48(5):575-576. PubMed ID: 30156326
    [No Abstract]   [Full Text] [Related]  

  • 7. IBD: To switch or not to switch: that is the biosimilar question.
    Danese S; Peyrin-Biroulet L
    Nat Rev Gastroenterol Hepatol; 2017 Sep; 14(9):508-509. PubMed ID: 28676708
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab biosimilar CT-P13 for inflammatory bowel disease.
    Bonovas S; Peyrin-Biroulet L; Danese S
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):373-375. PubMed ID: 29606565
    [No Abstract]   [Full Text] [Related]  

  • 9. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Felwick R; Cummings JRF
    Aliment Pharmacol Ther; 2017 May; 45(10):1370-1371. PubMed ID: 28417492
    [No Abstract]   [Full Text] [Related]  

  • 13. Biosimilars: in support of extrapolation of indications.
    Ebbers HC
    J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 May; 45(10):1372. PubMed ID: 28417494
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biosimilars in inflammatory bowel disease].
    Siegmund B; Atreya R; Bokemeyer B; Kruis W; Mudter J; Sander C; Schreiber S; Reindl W; Zeissig S; Kucharzik T
    Z Gastroenterol; 2016 Nov; 54(11):1217-1222. PubMed ID: 27711946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 17. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough?
    Allocca M; Fiorino G; Danese S
    Dig Dis Sci; 2017 Nov; 62(11):2964-2965. PubMed ID: 28776140
    [No Abstract]   [Full Text] [Related]  

  • 19. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
    Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
    J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of Biosimilars in Inflammatory Bowel Diseases.
    Feagins LA; Gold S; Steinlauf AF;
    Am J Gastroenterol; 2024 Feb; 119(2):229-232. PubMed ID: 37566893
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.